Dr Frank Sciurba

What Dr Frank Sciurba has said

• “These trial results suggest that targeting the IL-33 pathway with tozorakimab delivers meaningful clinical benefit in a trial representing a broad COPD population, independent of smoking status and eosinophilic levels. COPD has long been a difficult-to-treat disease with inherent heterogeneity and significant unmet need, with up to half of patients worldwide at risk of exacerbations, hospitalisations, cardiopulmonary events, and death — underscoring the importance of these results for advancing COPD science.”

  Professor of Pulmonary and Critical Care Medicine, University of Pittsburgh, Chief Investigator of LUNA programme · Respiratory (asthma/COPD) · 30 Sept 2026 · Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD ↗

• “These results add to the growing body of evidence that indicates tozorakimab delivered meaningful clinical benefits for COPD patients who urgently need new treatment options”

  University of Pittsburgh pulmonary medicine expert · Respiratory (asthma/COPD) · 30 Sept 2026 · AZ is three for three with COPD hope tozorakimab ↗

• “These results add to the growing body of evidence that indicates tozorakimab delivered meaningful clinical benefits for COPD patients who urgently need new treatment options.”

  Professor of Pulmonary and Critical Care Medicine at the University of Pittsburgh and chief investigator of the LUNA programme · Respiratory (asthma/COPD) · 30 Sept 2026 · AstraZeneca reports positive phase 3 data for tozorakimab in COPD ↗

• “The OBERON and TITANIA trials mark the first time we have seen a biologic in COPD achieve efficacy in a broad population across blood eosinophil thresholds, including in patients with baseline eosinophils below 150, and irrespective of smoking status. These unprecedented results, along with its favourable safety profile, underscore tozorakimab's potential as an innovative treatment for the millions of people living with COPD who remain at risk despite treatment with inhaled standard of care.”

  Professor of Pulmonary and Critical Care Medicine, University of Pittsburgh, Chief Investigator of the LUNA programme · Respiratory (asthma/COPD) · 29 Sept 2026 · Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials ↗

• “Reducing exacerbations is one of the most important goals in the treatment of COPD because flare-ups have a profound impact on patients' health, quality of life and long-term outcomes. It is encouraging to have an additional, safe therapy for patients who often struggle to breathe.”

  University of Pittsburgh · Respiratory (asthma/COPD) · 29 Sept 2026 · AZ’s COPD drug cuts flare-ups in two phase 3 trials ↗

Where Dr Frank Sciurba has been quoted

1. AstraZeneca lung drug gets ‘surprise’ win in COPD trialsbiopharmadive.com · 30 Sept 2026
2. Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPDastrazeneca.com · 30 Sept 2026
3. AZ is three for three with COPD hope tozorakimabpharmaphorum.com · 30 Sept 2026
4. AstraZeneca reports positive phase 3 data for tozorakimab in COPDpmlive.com · 30 Sept 2026
5. Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trialsastrazeneca.com · 29 Sept 2026
6. AZ’s COPD drug cuts flare-ups in two phase 3 trialsemjreviews.com · 29 Sept 2026

Related media coverage

Recent UK press coverage of their topics — not necessarily citing them directly.

• Radiation exposure linked to pulmonary hypertension after lung cancer treatmentMedical Xpress
• Lupin launches first triple combination inhaler for COPD in IndiaPharmacy Business
• Pulmonary and hepatic adverse effects associated with repeated intratracheal instillation of heated tobacco product emission-derived extractNature